论文信息 - LBA59 First-line nivolumab (NIVO) + ipilimumab (IPI) combined with 2 cycles of platinum-based chemotherapy (chemo) vs 4 cycles of chemo in advanced non-small cell lung cancer (NSCLC): Patient-reported outcomes (PROs) from CheckMate 9LA - 字舞流文

LBA59 First-line nivolumab (NIVO) + ipilimumab (IPI) combined with 2 cycles of platinum-based chemotherapy (chemo) vs 4 cycles of chemo in advanced non-small cell lung cancer (NSCLC): Patient-reported outcomes (PROs) from CheckMate 9LA

Ying Cheng | D. Carbone | L. Paz-Ares | T. Ciuleanu | T. John | M. Schenker | M. Reck | Shun Lu | M. Cobo | J. Bennouna | E. Richardet | S. Blum | B. Żurawski | J. Menezes | X. Sun | J. Yan | Y. Yuan | B. Padilla | A. Moisei